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Abstract
Chronic myeloid leukemia is a myeloproliferative syndrome characterized by the presence of the
Philadelphia chromosome (Ph), generated by a reciprocal translocation occurring between chromo-
somes 9 and 22 [t(9;22)(q34;q11)]. As a consequence, a fusion gene (bcr-abl) encoding a constitutive-
ly active kinase is generated. The first-line treatment consists onBCR-ABL inhibitors such as Imatinib,
Nilotinib and Dasatinib. Nevertheless, such treatment may lead to the selection of resistant cells.
Therefore, finding molecules that enhance the anti-proliferative effect of first-line drugs is of
value. Hyaluronan oligomers (oHA) are known to be able to sensitize several tumor cells to chemo-
therapy. We have previously demonstrated that oHA can revert Vincristine resistance in mouse
lymphoma and human leukemia cell lines. However, little is known about the role of oHA in hema-
tological malignancies. The aim of this work was to determine whether oHA are able to modulate
the anti-proliferative effect of Imatinib in chronic myeloid leukemia (CML) cell lines. The effect on
apoptosis and senescence as well as the involvement of signaling pathways were also evaluated.
For this purpose, the human CML cell lines K562 and Kv562 (resistant) were used. We demonstrated
that oHA sensitized both cell lines to the anti-proliferative effect of Imatinib increasing apoptosis and
senescence. Moreover, this effect would be accomplished through the down-regulation of the PI3K
signaling pathway. These findings highlight the potential of oHAwhen used as a co-adjuvant therapy
for chronic myeloid leukemia.
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Introduction
Chronic myeloid leukemia (CML) is a myeloproliferative syndrome
characterized by the presence of the Philadelphia chromosome (Ph),
generated by a reciprocal translocation occurring between chromo-
somes 9 and 22 [t(9;22)(q34;q11)]. As a consequence, a fusion gene
(bcr-abl) encoding a constitutively active kinase is generated. BCR-ABL
is an oncogenic protein responsible of the leukemogenic transform-
ation (Chandraa et al. 2011). For that reason, the first-line treatment
for CML consists on BCR-ABL inhibitors such as Imatinib, Nilotinib
and Dasatinib (Von Bubnoff and Duyster 2010; Wei et al. 2010).
One of the most used models for CML in preclinical studies of
Imatinib is the one employing the human cell line K562 (Wetzel
et al. 2005; Karimiani et al. 2014). In these cells, the anti-proliferative
effect of Imatinib is mediated by the induction of apoptosis as well as
senescence (Drullion et al. 2012). Such biological processes are two of
the most important mechanisms of tumor suppression. Apoptosis is a
type of cell death characterized by morphological and biochemical
changes, such as reduction of cell size, cytoplasmic membrane
blebbing, DNA fragmentation, exposure of phosphatidylserine and
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Senescence is a terminal differentiation stage associated with ageing,
stress conditions and tumor suppression. Senescent cells are character-
ized by molecular and morphological changes such as (i) irreversible
cell cycle arrest, (ii) increase in cellular granulation and size, (iii) the
presence of high β-galactosidase activity at suboptimal pH (SA-β-gal),
(iv) resistance to apoptosis and (v) the presence of senescence-
associated heterochromatin foci (SAHF) (Campisi and d’Adda di
Fagagna 2007; Nardella et al. 2011; Rodier and Campisi 2011).
Imatinib is a highly effective drug for the treatment of CML; how-
ever, the selection pressure that it exerts favors the development of re-
sistant cells (Wetzel et al. 2005; Mauro 2006; Comert et al. 2013).
Therefore, to find new molecular targets for enhancing the anti-
proliferative effect of Imatinib is of value.
Over the last years, it has been demonstrated that the extracellular
matrix plays an active role in tumor progression and multidrug resist-
ance (MDR) (Bissel and Radisky 2001; Wong and Rustgi 2013).
Hyaluronan (HA) is the main glycosaminogycan of the extracellular
matrix whose high levels correlate with poor prognosis and malig-
nancy development in several tumors (Boregowda et al. 2006;
Tammi et al. 2008; Toole 2009; Sironen et al. 2011; Bourguignon
2012; Auvinen et al. 2013; Provenzano and Hingorani 2013). The
interaction of HAwith its receptors, CD44 and RHAMM, stimulates
signaling pathways such as PI3K/Akt and MAPK, which are involved
in cell proliferation, migration and MDR (Toole 2004, 2009). Many
strategies aimed at mitigating the signals triggered by HA have been
studied. One of them is the use of hyaluronan oligomers (oHA)
which are able to bind HA receptors. However, due to their small
size, oHA cannot cross-link receptors, thus attenuating the signaling
triggered by HA (Toole 2004, 2009). It is known that oHA can sen-
sitize several tumor cell lines to the effect of chemotherapy (Misra
et al. 2003; Alaniz et al. 2006; Cordo-Russo et al. 2008; Slomiany,
Dai, Bomar, et al. 2009; Slomiany, Dai, Tolliver, et al. 2009). Never-
theless, little is known about the effect of oHA on CML cell lines. We
have previously demonstrated that oHA can sensitize the Vincristine-
resistant Kv562 cell line to the effect of Vincristine through the inhib-
ition of the P-glycoprotein (Pgp) and the PI3K pathway (Lompardía
et al. 2013). Besides, other authors have reported that oHA can also
sensitize the Adryamicin-resistant K562/A02 cells to the effect of
Adryamicin (Cui et al. 2009). However, nothing is known about
the effect of oHA on Imatinib therapy. Therefore, the aim of this
work was to evaluate whether oHA can sensitize CML cell lines to
the anti-proliferative effect of Imatinib by analyzing the tumor sup-
pression mechanisms involved. Our results indicate that the combin-
ation of oHA with Imatinib enhanced the anti-proliferative effect of
Imatinib increasing either apoptotic death or senescence, depending
on the concentration of Imatinib employed. When oHA were com-
bined with doses of Imatinib that were able to induce apoptosis by
themselves, oHA increased the levels of apoptosis, while the co-
incubation of oHA with a lower concentration of Imatinib enhanced
senescence induction. Moreover, the mechanism of tumor suppres-
sion involved would be regulated by PI3K. These findings highlight
the potential of oHA when used as co-adjuvant for first-line therapy
against CML.
Results
oHA sensitize K562 and Kv562 cells to the
anti-proliferative effect of Imatinib
Knowing that oHA were able to sensitize several tumor cell lines
to the effect of different chemotherapics (Cordo-Russo et al. 2008;
Slomiany, Dai, Bomar, et al. 2009), the effect of oHA in combination
with Imatinib on cell growth was assessed. To evaluate whether oHA
and Imatinib couldmodulate cell proliferation, the [3H]-thymidine up-
take was measured. PI3K implication was also analyzed. Several con-
centrations (0.125, 0.25, 0.5, 1, 2 and 4 μM) of Imatinib were tested
(data not shown), to choose three doses for each cell line to perform
the experiments. The highest concentration employed was selected
since it was the lowest dose which modulated cell proliferation
(0.5 µM for K562 and 2 µM for Kv562). Besides, two lower doses
were used to evaluate the ability of oHA to sensitize the cell lines to
the effect of Imatinib (0.125 and 0.25 µM for K562 and 0.25 and
0.5 µM for Kv562). In all cases, 300 μg/mL oHA was employed
(Lompardía et al. 2013).
Figure 1A, panel I shows that oHA sensitized K562 cells to the
anti-proliferative effect of 0.125 as well as 0.25 µM Imatinib. How-
ever, oHA + 0.5 µM Imatinib failed to increase significantly cell
growth inhibition showing only a trend. Panel II shows that oHA sen-
sitized Kv562 cells to the anti-proliferative effect of 0.5 as well as 2 µM
Imatinib while the combination of oHAwith the lower dose of Imati-
nib did not have any effect on cell growth.
Since oHA are able to decrease the pAkt/Akt ratio in both cell lines
(Lompardía et al. 2013), it was interesting to assess whether the inhib-
ition of PI3K signaling pathway could render K562 and Kv562 cells
sensitive to Imatinib. As shown in Figure 1B, Ly294002 sensitized
both cells lines to the anti-proliferative effect of Imatinib.
oAH enhance the pro-apoptotic effect of Imatinib
It has been reported that Imatinib induces apoptosis in K562 cells
(Drullion et al. 2012). Besides, oHA increase the apoptotic effect of
several chemotherapeutic drugs (Cordo-Russo et al. 2008; Slomiany,
Dai, Bomar, et al. 2009; Quin et al. 2011). Therefore, it was interesting
to evaluate whether the oHA sensitization to the anti-proliferative ef-
fect of Imatinib was mediated by increased levels of apoptosis. For this
purpose, cells were treated with oHA, Imatinib or combinations. After
48 h of incubation, membrane asymmetry (AnnexinV-PE), hypodi-
ploid content (subG1) and fragmentation of DNA were analyzed.
Figure 2A, panel I shows that oHA in combination with 0.25 as
well as 0.5 µM Imatinib enhanced the percentage of AnnexinV-PE
positive K562 cells while panel II demonstrates that only oHA plus
2 µM Imatinib increased such percentage in Kv562 cells. Moreover,
oHA in combination with the highest dose of Imatinib increased the
percentage of cells in subG1 peak as well as cells with DNA fragmen-
tation in both cell lines (Figure 2B and C).
Taking together, these results suggest that oHA sensitize both cell
lines to the pro-apoptotic effect of Imatinib only at the concentration
of Imatinib that is able to induce apoptosis by itself.
Ly294002 sensitizes both cell lines to the pro-apoptotic
effect of Imatinib
Since oHA reduce the pAkt/Akt ratio (Lompardía et al. 2013) and sen-
sitize both cell lines to the pro-apoptotic effect of Imatinib, it was of
value to evaluate if the inhibition of PI3K favors Imatinib-mediated
apoptosis. Therefore, cells were treated with Ly294002, Imatinib or
combinations and membrane asymmetry, hypodiploid content of
DNA and its fragmentation were assessed.
Figure 3 shows, for both cell lines, that PI3K inhibition with
Ly294002 in combination with Imatinib increased the percentage of
AnnexinV-PE positive cells, the percentage of cells in subG1 as well
as with DNA fragmentation. These results suggest that the inhibition
of PI3K enhances the pro-apoptotic effect of Imatinib.
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oHA enhance senescence induction mediated
by Imatinib
Due to the fact that Imatinib induces senescence in K562 cells
(Drullion et al. 2012) and oHA sensitize both cell lines to the anti-
proliferative effect of lower doses of Imatinib without modulating
apoptosis, senescence induction was analyzed. To this end, cells
were treated with oHA, Imatinib or combinations. After 48 h,
SA-β-gal and SAHF were evaluated. It is worth to note that the
increased activity of β-galactosidase (still detectable at suboptimal
pH) is the main marker of senescence (SA-β-gal). Furthermore,
SAHF are generated due to the characteristic genomic damage that
occurs in senescence.
The co-treatment with oHA plus the highest levels, 0.5 or 2 µM
Imatinib, did not have any effect neither on SA-β-gal nor on SAHF
in K562 and Kv562 cells, respectively (Figure 4). Nevertheless,
co-incubation of oHA with lower doses of Imatinib (0.125 and
0.25 µM in K562 and 0.5 µM in Kv562) increased the percentage of
SA-β-gal-positive cells as well as the number of cells with SAHF
(Figure 4). These results suggest that oHA sensitized both cell lines
to the senescent effect of low doses of Imatinib.
Furthermore, the implication of PI3K on senescence induction was
analyzed. SA-β-gal and SAHF were evaluated after 48 h of incubation
with Ly294002, Imatinib or combinations. The co-treatment with
Ly294002 + Imatinib did not have any effect on senescence induction
(data not shown).
The co-treatment with oHA and Imatinib decreases
the pAkt/Akt ratio
Imatinib as well as oHA abrogate phosphorylation of Akt and ERK in
K562 cells (Machado-Neto et al. 2011; Lompardía et al. 2013; Elfineh
et al. 2014). Moreover, oHA reduced the pAkt/Akt ratio without affect-
ing the pERK/ERK ratio in Kv562 cells (Lompardía et al. 2013). There-
fore, both cell lines were treated with oHA, Imatinib or combinations for
24 h and Akt and ERK phosphorylation was analyzed by western blot.
Fig. 1. Effect of oHA and Imatinib on both cell lines proliferation. (A) K562 (I) and Kv562 (II) cells were treated with 300 µg/mL oHA, Imatinib or combinations for 48 h.
(B) 5 µM Ly294002 (PI3K inhibitor) was used to assess if PI3K inhibition was involved in the abrogation of cell growth. Results are expressed as: Cell proliferation
percentage = (treated cpm × 100/untreated cpm)− 100. Bars representmeans ± SD of at least five independent experiments ###P < 0.001, ##P < 0.01 and #P < 0.05 vs.
untreated while ***P < 0.001, **P < 0.01 and *P < 0.05 between the different treatments as indicated.
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Fig. 2. Effect of oHA and Imatinib on apoptosis induction in K562 and Kv562 cell lines. To determine if oHA and Imatinib co-treatment enhanced the induction of
apoptosis, both cell lines were treated with these compounds for 48 h and then three different parameters were analyzed. (A) The membrane asymmetry was
evaluated by FC. After treatments, cells were stained with Annexin-V-PE/7AAD. Bars represent means ± SD of Annexin-V positive cells of three independent
experiments ##P < 0.01 and #P < 0.05 vs. untreated while *P < 0.05 and ns P > 0.05 between the different treatments as indicated. (B) The hypodiploid content
was evaluated by FC. Cells were fixed with ethanol and stained with DAPI. Bars represent means ± SD of cells in subG1 peak of three independent experiments
##P < 0.01 and #P < 0.05 vs. untreated while **P < 0.01 and *P < 0.05 between the different treatments as indicated. (C) DNA fragmentation was analyzed by
fluorescence microscopy. K562 (I) and Kv562 (II) cells were fixed with PFA and stained with DAPI. Bars represent means ± SD of cells with DNA fragmentation of
three independent experiments ###P < 0.001 and ##P < 0.01 vs. untreated while **P < 0.01 and ns P > 0.05 between the different treatments as indicated.
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In K562 cells, oHA, Imatinib as well as their co-incubation
treatment decreased pERK/ERK ratio respect to untreated condi-
tions. However, no significant differences were observed between
them. In Kv562 cells, none of the treatments (oHA, Imatinib or
their combinations) modulated the phosphorilation of ERK respect
to untreated. Therefore, oHA and Imatinib co-treatment did not
have any effect on the pERK/ERK ratio when compared with each
treatment alone (data not shown). Similar results were found for
oHA + 0.25 or 0.5 µM Imatinib for the pAkt/Akt ratio in K562
and Kv562 cells, respectively (Figure 5A). However, the combination
of oHA with the highest doses of Imatinib employed (0.5 µM in
K562 and 2 µM in Kv562) abrogated the phosphorylation of Akt
in both cell lines.
Discussion
CML represents a 15% of all leukemias, with an incidence of 2 cases/
100,000 people per year. Although Imatinib is a highly effective drug,
after some time, the selection of resistant cells may occur, leading to
therapeutic failure. Current studies on the biology of CML are vital
to find new molecular targets to improve therapies. Since multiple fac-
tors may contribute to chemoresistance, the impact of extracellular
matrix components on this process has become of great interest (Bissel
and Radisky 2001; Cordo-Russo et al. 2008).
HA is the main glycosaminoglican of the extracellular matrix and
its levels are known to correlate with poor prognosis (Toole 2009; Sir-
onen et al. 2011; Auvinen et al. 2013). Contrarily, oHA can block sev-
eral biological mechanismsmediated byHA. Therefore, it was of value
to assess whether oHA could improve the Imatinib effect on CML cell
lines. For this purpose, we used the K562 and Kv562 cell lines. The
former is sensitive to Imatinib and several chemotherapeutic drugs
such as Vincristine and Doxorubicin while the latter is multidrug re-
sistant due to Pgp functionality and PI3K over-activation (Lompardía
et al. 2013). In this work, we demonstrated for the first time that oHA
enhanced the anti-proliferative effect of Imatinib increasing apoptosis
and senescence induction in both cell lines (Figure 6A).
Initially, several concentrations of Imatinib were evaluated showing
that Kv562 cells required higher doses than K562 cells to attain a simi-
lar effect. This result was expected since Kv562 cells express Pgp and
Imatinib can be extruded through this efflux pump (Czyzewski and
Styczynski 2009; Silva et al. 2013). Imatinib abrogated the prolifer-
ation of K562 and Kv562 cells inducing apoptosis and senescence.
Moreover, the BCR-ABL inhibitor reduced pAkt/Akt ratio in both
cell lines while it only decreased the pERK/ERK ratio in K562 cells.
Our results are in agreement with several studies performed in K562
cells (Machado-Neto et al. 2011; Li et al. 2013; Elfineh et al. 2014).
However, this is the first study reporting the effect of Imatinib on
Kv562 cells.
Fig. 3. Implication of PI3K in apoptosis induced by Imatinib. To determine if the inhibition of PI3K enhanced the induction of apoptosis, both cell lines were treated
with Ly294002, Imatinib or combinations for 48 h. (A) Evaluation of membrane asymmetry. After treatments, cells were stained with Annexin-V-PE/7AAD and
analyzed by FC. Bars represent means ± SD of Annexin-V positive cells of three independent experiments ##P < 0.01 and #P < 0.05 vs. untreated while
***P < 0.001, **P < 0.1 and *P < 0.05 between the different treatments as indicated. (B) Evaluation of hypodiploid cells. Cells were fixed with ethanol and stained
with DAPI. Twenty thousand events were acquired by FC. Bars represent means ± SD of cells in subG1 peak of three independent experiments ###P < 0.001 and
##P < 0.01 vs. untreated while ***P < 0.001, **P < 0.01 and *P < 0.05 between the different treatments as indicated. (C) Analysis of DNA fragmentation. K562 (I) and
Kv562 (II) cells were fixed with PFA and stained with DAPI. For each treatment, 200 cells were counted by fluorescence microscopy. Bars represent means ± SD of
cells with DNA fragmentation of three independent experiments ###P < 0.001, ##P < 0.01 and P < 0.05 vs. untreated while ***P < 0.001 and P < 0.01 between the
different treatments as indicated.
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The role of oHA has previously been described (Lompardía et al.
2013). Briefly, in K562 cells, oHA-CD44 interaction partially abro-
gates PI3K/Akt and MEK/ERK signaling pathways reducing cell
growth. In Kv562 cells, oHA are known to reduce MDR by two dif-
ferent mechanisms, the inhibition of Pgp mediated by CD44 and the
inhibition of PI3K mediated by RHAMM. We suggest that all such
effects of oHA would be mediated by the inhibition of HA inter-
action with its receptors. Moreover, we previously demonstrated
that oHA are able to displace HA in both cell lines (Lompardía
et al. 2013).
When combining the highest doses of Imatinib with oHA, a major
anti-proliferative effect was obtained. Moreover, this co-treatment
induced a dramatic decrease in the pAkt levels with a significant in-
duction of apoptosis in both cell lines. These results are in agreement
with Slomiany, Dai, Bomar, et al. (2009) who demonstrated that
oHA sensitized malignant peripheral nerve sheath tumors to apo-
ptotic death.
Although the co-incubation of the lowest concentrations of
Imatinib with oHA also reduced both cell lines proliferation, this
co-treatment did not modify the levels of apoptosis induced by each
compound alone. In this case, the mechanism of tumor suppression
involved was senescence. These results are in accordancewith previous
works carried out in our laboratory which demonstrated that oHA
sensitize Kv562 cells to the senescent effect of Vincristine (Lompardía
et al. 2013). Moreover, the combinations of low doses of Imatinib
plus oHA did not show a significant abrogation of the pAkt/Akt
ratio compared with Imatinib or oHA alone while the co-treatment
with high doses of Imatinib plus oHA prevented the phosphorylation
of Akt. Taking into account these results, we postulate that the induc-
tion of apoptosis could be mediated by the sharp drop in pAkt levels
while senescence would be triggered by partial reductions in pAkt
(Figure 6B).
Considering that high doses of Imatinib were able to generate sig-
nificant levels of apoptosis while low doses increased only the induc-
tion of senescence, we hypothesized that Imatinib targets the tumor
suppression mechanism while oHA would enhance the pathway af-
fected by Imatinib.
Taking into consideration the hypothesis about the role of Akt
phophorilation on apoptosis induction, it was interesting to evaluate
whether the inhibition of PI3K enhanced the pro-apoptotic effect of
Fig. 4. Evaluation of senescence induction. To determine if oHA enhanced the senescence induced by Imatinib, both cell lines were treated with 300 µg/mL oHA,
Imatinib or combinations for 48 h. SA-β-gal activity (A) and SAHF (B) (magnification 400×) were evaluated. Bars represent means ± SD of three independent
experiments ###P < 0.001 and ##P < 0.01 vs. untreated while ***P < 0.001, P < 0.01 and *P < 0.05 between the different treatments as indicated. Arrows indicate
nuclei with SAHF. This figure is available in black and white in print and in color at Glycobiology online.
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Imatinib. We demonstrated that Ly294002 sensitized both cell lines to
the anti-proliferative and pro-apoptotic effect of Imatinib. These re-
sults correlate with previous reports showing an improvement of the
Imatinib effect achieved by the inhibition of PI3K (Ciarcia et al.
2013). Moreover, several reports indicate that an over-activation of
PI3K is involved in apoptosis evasion and Imatinib resistance
(Chang et al. 2003; McCubrey et al. 2006; Quentmeier et al. 2011).
Hence, abrogating this signaling pathway would be crucial for an op-
timal effect of Imatinib. Considering that HA increased PI3K activity
in both cell lines (Lompardía et al. 2013) and it is has been demon-
strated that the bone marrow presents high levels of HA (Goncharova
et al. 2012; Solis et al. 2012) (Figure 6AI), preventing the signaling
triggered by HAwould be a useful strategy to improve the effect of Im-
atinib (Figure 6AII). In this sense, oHA represent a valuable tool to be
used as a potential co-adjuvant in the therapy against CML.
Conclusion
Combination of Imatinib with oHA enhanced the anti-proliferative
effect of the BCR-ABL inhibitor in both cell lines. This effect was
mediated by sensitization either to apoptotic death or senescence de-
pending on the concentration of Imatinib employed. When oHAwere
combined with doses of Imatinib that induced apoptosis itself, oHA
increased the levels of apoptosis, while co-incubation of oHA
with lower concentrations of Imatinib enhanced the induction of
senescence. Moreover, the mechanism of tumor suppression involved
would be regulated by PI3K activation. These findings highlight




Human CML cell lines K562 (VCR sensitive) and Kv562 (VCR re-
sistant) were grown in suspension cultures at 37°C in a 5% CO2
atmosphere with RPMI-1640 supplemented with 10% heat inacti-
vated fetal bovine serum (FBS), 2 mM L-glutamine, 10 mM HEPES
buffer, 5 × 10−5 M 2-mercaptoethanol, 100 µg/mL streptomycin and
100 IU/mL penicillin (RPMI-C). The resistant cell line was cultured
in the presence of 150 ng/mL (162 nM) VCR (Lompardía et al. 2013).
Reagents
Recombinant low-molecular weight (LMW; 2.5–3 × 105 Da) HA (CPN
spol.s.r.o Czech Republic) was supplied by Farmatrade (Argentina).
Hyaluronidase Bovine testes (#H3884, Type IV-S, lyophilized powder, es-
sentially salt-free), X-gal, LY294002 and 4′,6-diamidino-2-phenylindole
(DAPI) were purchased from Sigma-Aldrich. Imatinib was kindly pro-
vided by Dr Irene Larripa. Antibodies (Ab) against pAkt, Akt, pERK,
ERK, β-Actin, anti-rabbit secondary horseradish peroxidase and anti-goat
secondary horseradish peroxidase Abs were purchased from Santa Cruz
Biotechnology. [3H]-Thymidine was purchased from Perkin-Elmer
(Boston). RPMI 1640, L-glutamine, streptomycin and penicillin were pur-
chased from Invitrogen (Argentina). PE Annexin VApoptosis Detection
Kit I was purchased from BD Pharmingen™ (BD Bioscience).
Fig. 5. Modulation of the pAkt/Akt ratio. (A) K562 and Kv562 cells were treated with 300 µg/mL oHA, 0.25 or 0.5 µM Imatinib or combinations for 24 h. Akt
phosphorylation was evaluated by WB. Results are expressed as: pAkt/Akt ratio = [(pAkt/β-actin)/(Akt/β-actin)]treated/[(pAkt/β-actin)/(Akt/β-actin)]untreated. Bars
represent means ± SD of at least three independent experiments #P < 0.05 and ns = no significant (P > 0.05) vs. untreated. (B) Both cell lines were treated with
300 µg/mL oHA, 0.5 or 2 µM Imatinib or combinations for 24 h. The phosphorylation of Akt was evaluated by WB. Results are expressed as pAkt/Akt ratio
(calculated as in A). Bars represent means ± SD of at least three independent experiments, ###P < 0.001 and #P < 0.05 vs. untreated while **P < 0.01 and
*P < 0.05 between the different treatments as indicated.
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Preparation of oHA
The size distribution of the oHA was from HA4 tetrasaccharides to
HA14 oligosaccharides. They were generated as described previously
(Cordo-Russo et al. 2008). Briefly, oligosaccharides were obtained
after enzymatic digestion of LMW-HA (5 mg/mL) withHyaluronidase
bovine testes employing 500 U/mg of HA during 24 h at 37°C. The
reaction was stopped by heat denaturation for 5 min. The suspension
was then filtered through 0.22 µm filter and then hyaulonidase and
oHA were separated using Centricon™ with 10 kDa pore size. The
size of oHA was determined by HPAEC-PAD.
Cell proliferation
Cell proliferation was analyzed by the [3H]-thymidine uptake assay
evaluated at 48 h in 96 wells microtiter plates (Lompardía et al.
2013). Fifty thousand cells per well (250,000 cells/mL) were used.
Cells were grown at 37°C in a 5% CO2 atmosphere with RPMI-C,
300 μg/mL oHA, 5 μM Ly294002, Imatinib (2; 0.5; 0.25 or
0.125 µM) or combinations. After pulsing with 1 μCi [3H]-thymidine
for 6 h, cells were harvested and counted in a liquid scintillation coun-
ter (Beckman, MD). Results were calculated from the mean cpm of
[3H]-thymidine incorporated in triplicate cultures. Untreated cells
represented 100% cell survival. Cell viability at the beginning of the
experiment was >95%, as assessed by the Trypan blue dye.
Evaluation of apoptosis
Cells were treated with RPMI-C, 300 μg/mL oHA, 5 μM Ly294002,
Imatinib (2; 0.5; 0.25 or 0.125 µM) or combinations for 48 h at
37°C in a 5% CO2 atmosphere. Then, membrane asymmetry, DNA
fragmentation and hypodiploid DNA content were evaluated. For
membrane asymmetry, the PE Annexin V Apoptosis Detection Kit I
(BD Biosciences) was used following the manufacturer’s instructions.
A Pas III flow cytometer (Partec, Germany) was used to acquire data
which were analyzed with theWinMDI 2.8 software (Scripps Institute,
La Jolla). For DNA fragmentation and hypodiploid DNA content,
cells were stained with DAPI and evaluated using fluorescence micros-
copy (Olympus BX51, America Inc.) and flow cytometry (Pas III
flow cytometer, Partec, Germay), respectively (Cavaliere et al. 2009;
Papademetrio et al. 2014).
Evaluation of senescence
Cell senescence was analyzed by SA-β-gal and SAHF (Debacq-
Chainiaux et al. 2009). For SA-β-gal, cells were incubated with
RPMI-C, 300 μg/mL oHA, 5 μM Ly294002, Imatinib (2; 0.5; 0.25
or 0.125 µM) or combinations at 37°C in a 5% CO2 atmosphere.
After 48 h, cells were fixed with PBS plus 2% PFA and washed with
PBS. Each vial was incubated for 24 h at 37°C with 1 mL of staining
solution (1 mg/mL X-gal, 5 mM potassium ferricyanide, 5 mM potas-
sium ferrocyanide, 2 mM MgCl2, 150 mM NaCl, 30 mM citric acid/
phosphate, pH = 6). Cells were washed twice with PBS and the
SA-β-gal activity was evaluated using an Olympus BX51 (America
Inc.) microscope. Blue cells were considered positive. For each condi-
tion, 200 cells were counted and the percentage of SA-β-gal-positive
cells was calculated (Debacq-Chainiaux et al. 2009; Drullion et al.
2012). For SAHF, cells were subjected to a similar procedure. After
48 h, cells were fixed, washed and incubated with 1 μg/mL DAPI in
PBS plus 0.2% Triton X-100 for 30 min at room temperature. Cells
were analyzed by fluorescence microscopy (Olympus BX51, America
Inc.) for SAHF (Yang et al. 2012).
Fig. 6. Suggestedmechanism of action of oHA in combination with Imatinib in K562 and Kv562 cells. (A) (I) Proposed role of HA and BCR-ABL in the induction of cell
proliferation. In K562 cells, the HA-CD44 interaction as well as BCR-ABL might activate PI3K/Akt and MEK/ERK signalling pathways inducing cell proliferation. In
Kv562 cells, the HA-RHAMM interaction would activate CD44 or other cell surface receptors triggering PI3K/Akt pathway enhancing cell proliferation. BCR-ABL
also activates PI3K/Akt increasing Kv562 cells growth. Moreover, HA abrogates senescence induction while BCR-ABL prevents apoptosis and senescence
induction in both cell lines. (II) Proposed mechanism of action of oHA and Imatinib. oHA would block the effect of HA while Imatinib inhibits BCR-ABL activity.
Consequently, the combination of both compounds decreases K562 cells proliferation due to down-regulation of PI3K/Akt and MEK/ERK pathways. Moreover,
the co-treatment with oHA plus Imatinib enhances apoptosis and senescence induction. Furthermore, oHA revert multidrug resistance of Kv562 cells through
Pgp inhibition and the decrease of pAkt. Therefore, oHA sensitized Kv562 cells to the anti-proliferative effect of Imatinib inducing apoptosis and senescence. (B)
We suggest that a high activity of PI3K would favor cell proliferation, while partial or total inhibition of this pathway might induce senescence or apoptosis,
respectively. This figure is available in black and white in print and in color at Glycobiology online.
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Western blot
Cells were treated with RPMI-C, 300 μg/mL oHA, Imatinib (2; 0.5;
0.25 or 0.125 µM) or combinations for 24 h at 37°C in a 5% CO2
atmosphere. Cells were then lysed with hypotonic buffer. After centri-
fugation, equal amounts of protein were resolved by SDS–polyacryl-
amide gel electrophoresis and transferred onto a PVDF membrane
(Osmonics Inc., Gloucester, MA). The membrane was blocked and in-
cubated with specific antibodies to p-Akt, Akt, p-ERK, ERK or
β-Actin overnight at 4°C followed by incubation with a horseradish
peroxidase-labeled secondary antibody for 2 h at 37°C. The reaction
was developed using a chemiluminescent detection system. Gel images
obtained with a digital camera were subjected to densitometric ana-
lysis using the Image Scion Software (Scion Corporation) (Lompardía
et al. 2013).
Statistical analysis
All results were analyzed by one-way ANOVA and Bonferroni’s test.
The analysis was performed using Prism software (Graph Pad, San
Diego, CA). P-values <0.05 were regarded as statistically significant
(Lompardía et al. 2013).
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